drugset / Trial / NCT04480190
Neoadjuvant Therapy in Biliary Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.
Timeline
- Start
- 2021-02-04
- Primary completion
- 2022-04-04
- Completion
- 2022-04-04
Outcome
Outcome not reported
Stopped (Enrollment): “Difficulty accruing”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT | Unknown | 225 mg/m2 | Intravenous |